Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer

In advanced lung cancer, epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) have extraordinary clinical efficacy. However, their usefulness is severely compromised by drug resistance mediated by various mechanisms, the most important of which is the secondary EGFR T790M mutation. The mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongjian, Tong, Christy Wing-Sum, Leung, Yee, Wong, Man-Hon, To, Kenneth Kin-Wah, Leung, Kwong-Sak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712561/
https://www.ncbi.nlm.nih.gov/pubmed/29238696
http://dx.doi.org/10.3389/fonc.2017.00288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712561/
https://www.ncbi.nlm.nih.gov/pubmed/29238696
http://dx.doi.org/10.3389/fonc.2017.00288

Ejemplares similares